Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bavarian Nordic ASCHIX:BAVAC 79 Debt-to-EBITDA is 0.18 as of Mar. 2026, which is 18% below its 10-year median of 0.22. GuruFocus rates CHIX:BAVAC with a GF Score™ of 79/100 and a GF Value™ of kr167.43. The stock has 2 warning signs investors should review. Among 291 Biotechnology companies, Bavarian Nordic AS ranks better than 88.32% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Bavarian Nordic AS's Debt-to-EBITDA or its related term are showing as below:
CHIX:BAVAc'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -6.81 Med: 0.22 Max: 13.18
Current: 0.06
During the past 13 years, the highest Debt-to-EBITDA Ratio of Bavarian Nordic AS was 13.18. The lowest was -6.81. And the median was 0.22.
CHIX:BAVAc's Debt-to-EBITDA is ranked better than 88.32% of 291
companies
in the Biotechnology industry
Industry Median: 1.14
vs CHIX:BAVAc: 0.06
Bavarian Nordic AS (CHIX:BAVAc) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Bavarian Nordic AS Debt-to-EBITDA Related Terms
Bavarian Nordic AS Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Bavarian Nordic AS's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:BAVAC vs VRTX, REGN, ALNY: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Bavarian Nordic AS's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bavarian Nordic AS Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bavarian Nordic AS's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bavarian Nordic AS's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Bavarian Nordic AS (CHIX:BAVAC) has a Debt-to-EBITDA of 0.18 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Bavarian Nordic AS. This is 18% below median its historical median of 0.22. According to the industry distribution chart, Bavarian Nordic AS ranks #34 out of 291 companies in the Biotechnology industry, placing it in the top 11.7%.
Is Bavarian Nordic AS's Debt-to-EBITDA too high?
Bavarian Nordic AS's current Debt-to-EBITDA of 0.18 is 18% below median its 10-year median of 0.22. The Biotechnology industry median Debt-to-EBITDA is 1.14. Bavarian Nordic AS's value of 0.18 is 84.2% below this industry median. Based on the distribution chart, Bavarian Nordic AS ranks #34 out of 291 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bavarian Nordic AS has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does Bavarian Nordic AS's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bavarian Nordic AS ranks #34 out of 291 companies for Debt-to-EBITDA. This places Bavarian Nordic AS in the top 12% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.14. Bavarian Nordic AS's value of 0.18 is 84.2% below this benchmark. While the company's 10-year median is 0.22 vs. the industry median of 1.14, Bavarian Nordic AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.14, based on 291 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bavarian Nordic AS's current Debt-to-EBITDA of 0.18 is 84.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Bavarian Nordic AS. For the Biotechnology industry, the median Debt-to-EBITDA is 1.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bavarian Nordic AS's current Debt-to-EBITDA is 0.18, which is 18% below median its own 10-year median of 0.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bavarian Nordic AS stock overvalued right now?
Bavarian Nordic AS (CHIX:BAVAC) has a current Debt-to-EBITDA of 0.18. The stock's GF Value™ is kr167.43, compared to a current price of kr188.30 — trading 12.5% above its estimated fair value. The current Debt-to-EBITDA is 0.18, which is 18% below median its 10-year median of 0.22 and 84.2% below the Biotechnology industry median of 1.14. Bavarian Nordic AS's overall GF Score™ is 79/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Bavarian Nordic AS (CHIX:BAVAC), the current Debt-to-EBITDA is 0.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bavarian Nordic AS (CHIX:BAVAC) Overvalued in 2026?
Based on GuruFocus' analysis, Bavarian Nordic AS stock appears to be overvalued.
The current stock price of kr188.30 is trading 12.5% above its estimated GF Value™ of kr167.43.
Key valuation signals for CHIX:BAVAC:
Debt-to-EBITDA: 0.18 (18% below median its 10-year median of 0.22)
GF Value™: kr167.43 vs. price of kr188.30 (12.5% above fair value)
Industry Position: 84.2% below the Biotechnology median (#34 of 291)
No single metric tells the full story. See the CHIX:BAVAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bavarian Nordic AS is a biotechnology company focused on the research, development, manufacturing, and commercialization of life-saving vaccines. The group is a supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and has a portfolio of travel vaccines. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets. Its products include Encepur, Jynneos, Rabipur, Vaxchora, VIMKUNYA and Vivotif.
79GF Score
Get the complete analysis for CHIX:BAVAC
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:BAVAC has been successfully added to your 
